FibroGen reports FY2022 revenue $140.7M, net loss $293.7M; China roxadustat sales up 74%

KYNTRA BIO, INC.

2022-FY EPS reported -$3.14 revenue$140,734,000

Total revenue $140.7M in 2022 vs $235.3M in 2021 (which included $120M milestone from Astellas).
Net loss $293.7M ($3.14 per share) vs $290.0M prior year; Q4 net loss $66.2M ($0.70 per share).
China roxadustat net product revenue $82.9M in 2022, up 74% YoY; Q4 $23.4M, up 328% YoY.
Cash, equivalents, investments, and AR $442.7M at Dec 31, 2022; funded into 2H 2024.
Five pivotal Phase 3 readouts expected in 2023: pamrevlumab in DMD and IPF, roxadustat in MDS and CIA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KYNTRA BIO, INC. reported the fourth quarter of 2022 results: revenue $34.4 million, net income $66.2 million net loss, EPS $0.70 net loss per basic and diluted share.

Period: the fourth quarter of 2022
Revenue: $34.4 million
Net income: $66.2 million net loss
EPS: $0.70 net loss per basic and diluted share
Result: reported results

Exact text from the filing

Total revenue for the fourth quarter of 2022 was $34.4 million, as compared to $16.5 million for the fourth quarter of 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KYNTRA BIO, INC. reported the full year 2022 results: revenue $140.7 million, net income $293.7 million net loss, EPS $3.14 net loss per basic and diluted share.

Period: the full year 2022
Revenue: $140.7 million
Net income: $293.7 million net loss
EPS: $3.14 net loss per basic and diluted share
Result: reported results

Exact text from the filing

Total revenue for 2022 was $140.7 million as compared to $235.3 million in 2021, which included $120 million of milestone payments from Astellas related to the EU approval of roxadustat.

View on SEC.gov

Browse all earnings releases →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-004644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.